ACCEL Lite: ACC.23 Late-Breaker: Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk

<p class="MsoNormal">Statin intolerance is one of the most vexing problems encountered by patients and providers. The CLEAR Outcomes trial directly addresses this problem, using a drug, bempedoic acid, that works only in the liver, thereby reducing the potential for side effects. </p> <p class="MsoNormal">In this interview, Steven E. Nissen MD, MACC and Laxmi Mehta MD, FACC, discuss Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk. </p> <p class="MsoNormal"><a href= "https://itunes.apple.com/us/podcast/eagles-eye-view-your-weekly-cv-update-from-acc-org/id1274635046" target="_blank" rel="noopener">Subscribe on Apple</a> <u>Podcasts</u> | <a href= "https://play.google.com/music/listen#/ps/I6dtkumvaipematzgzmbph2koiq" target="_blank" rel="noopener">Subscribe on Google Play</a> <u>|</u> <a href= "http://www.acc.org/education-and-meetings/products-and-resources/accel-audio" target="_blank" rel="noopener">Subscribe to ACCEL</a> </p>